• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

IBM’s CEO disagrees with JPMorgan CEO Jamie Dimon’s disdain for texting in meetings: ‘Telling people they can't use their technology would be weird’

2

Richard Branson double-booked his own job interview. The candidate stuck in traffic with him for 2.5 hours is now Virgin's CEO

3

Tech billionaires and executives like Evan Spiegel and Peter Thiel are publicly shielding their children from the products that made them rich

1

IBM’s CEO disagrees with JPMorgan CEO Jamie Dimon’s disdain for texting in meetings: ‘Telling people they can't use their technology would be weird’

2

Richard Branson double-booked his own job interview. The candidate stuck in traffic with him for 2.5 hours is now Virgin's CEO

3

Tech billionaires and executives like Evan Spiegel and Peter Thiel are publicly shielding their children from the products that made them rich
HealthCoronavirus

A new study suggests that the Omicron variant is over four times more transmissible in its early stage than Delta

By
Kanoko Matsuyama
Kanoko Matsuyama
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Kanoko Matsuyama
Kanoko Matsuyama
and
Bloomberg
Bloomberg
Down Arrow Button Icon
December 8, 2021, 11:47 PM ET
Add Fortune on Google for similar content.

The omicron variant of COVID-19 is 4.2 times more transmissible in its early stage than delta, according to a study by a Japanese scientist who advises the country’s health ministry, a finding likely to confirm fears about the new strain’s contagiousness.

Hiroshi Nishiura, a professor of health and environmental sciences at Kyoto University who specializes in mathematical modeling of infectious diseases, analyzed genome data available through November 26 in South Africans in Gauteng province. 

“The omicron variant transmits more, and escapes immunity built naturally and through vaccines more,” Nishiura said in his findings, which were presented at a meeting of the health ministry’s advisory panel on Wednesday. 

Concerns are swirling globally that omicron could deal the world a bigger blow than even delta, and the World Health Organization has cautioned that it could fuel surges with “severe consequences.” But a jump in cases in South Africa in the wake of the variant’s emergence hasn’t yet overwhelmed hospitals, leading to some optimism that it may only cause mostly mild illness. Pfizer Inc. and BioNTech SE also said this week that a booster dose of their vaccine could fortify protection against the strain.

Nishiura’s study hasn’t been peer-reviewed and published in a scientific journal. The new analysis was conducted using the same method he used in a July study published by the Eurosurveillance medical journal on delta’s predicted dominance ahead of the Tokyo Olympics.

Hundreds of researchers globally are racing to understand the new variant, which is the most differentiated strain yet among the five variants of concern identified by the WHO since the pandemic began.

Cases in South Africa have rapidly increased to as many as nearly 20,000 a day since the country first reported omicron’s discovery two weeks ago. The number of COVID cases in the nation had remained low in the preceding weeks, despite only 26% of the population being fully vaccinated, according to Bloomberg’s Vaccine Tracker. 

“The vaccination rate was less than 30% and many people were probably naturally infected,” Nishiura said. “We need to pay close attention to future trends to see if the same thing will happen in countries where mRNA vaccines are used at a high rate.”  

Never miss a story: Follow your favorite topics and authors to get a personalized email with the journalism that matters most to you.

About the Authors
By Kanoko Matsuyama
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Latest in Health


    Most Popular

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.